An interventional study of Ultra-Protective Ventilation Facilitated by Extracorporeal Support and Lung-Protective Ventilation (LPV) in Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication and Mechanical Ventilation Pressure High, sponsored by University Health Network, Toronto. Recruiting at 103 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Respiratory Insufficiency by University Health Network, Toronto — 7 open to participants now, 8 under way, none of them phase 3. Respiratory Insufficiency · University Health Network, Toronto.
Among the 14 studies in Respiratory Insufficiency by University Health Network, Toronto, this one is one of 3 that started in 2023, is one of 7 with no phase, and was the 9th registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →7 of the 14 studies in Respiratory Insufficiency by University Health Network, Toronto are open now, in 10 countries. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
University Health Network, Toronto · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 6,250 is above the median of 60 across 861 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 22 across the 8 interventional studies, 45 across the 6 observational. Of the 6 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Health Network, Toronto is the lead sponsor of 1,441 studies on the registry; 298 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
3 of the studies in Respiratory Insufficiency by University Health Network, Toronto that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07518862University Health Network, TorontoHeart Rate VAriability as a MaRker for tItrATing hIgh flOw Nasal Cannula Therapy | 2026-11 |
| NCT04524585University Health Network, TorontoPartial Neuromuscular Blockade in Acute Hypoxemic Respiratory Failure | 2026-12-01 |
| NCT05440851University Health Network, TorontoPlatform of Randomized Adaptive Clinical Trials in Critical Illness | 2027-03-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Respiratory Insufficiency by University Health Network, Toronto, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
PRACTICAL is a randomized multifactorial adaptive platform trial for acute hypoxemic respiratory failure (AHRF). This platform trial will evaluate novel interventions for patients with AHRF across a range of severity states (i.e., not intubated, intubated with lower or higher respiratory system elastance, requiring extracorporeal life support) and across a range of investigational phases (i.e., preliminary mechanistic trials, full-scale clinical trials). AHRF is a common and life-threatening clinical syndrome affecting millions globally every year. Patients with AHRF are at high risk of death and long-term morbidity. Patients who require invasive mechanical ventilation are at risk of ventilator-induced lung injury and ventilator-induced diaphragm dysfunction. New treatments and treatment strategies are needed to improve outcomes for these very ill patients.
Utilizing advances in Bayesian adaptive trial design, the platform will facilitate efficient yet rigorous testing of new treatments for AHRF, with a particular focus on mechanical ventilation strategies and extracorporeal life support techniques as well as pharmacological agents and new medical devices.
The platform is designed to enable evaluation of novel interventions at a variety of stages of investigation, including pilot and feasibility trials, trials focused on mechanistic surrogate endpoints for preliminary clinical evaluation, and full-scale clinical trials assessing the impact of interventions on patient-centered outcomes.
A domain is defined as a set of interventions that are intended to act on specific mechanisms of injury using different variations of a common therapeutic strategy. A domain may also be a non-interventional study that addresses observational research questions by collecting specific data or outcomes that are not collected as part of other domains. Domains are intended to function independently of each other, allowing independent evaluation of multiple therapies and mechanistic pathways within the same patient.
Once feasibility is established, Bayesian adaptive statistical modelling will be used to evaluate treatment efficacy at regular interim adaptive analyses of the pre-specified outcomes for each intervention in each domain. These adaptive analyses will compute the posterior probabilities of superiority, futility, inferiority, or equivalence for pre-specified comparisons within domains. Each of these potential conclusions will be pre-defined prior to commencing the intervention trial. Decisions about trial results (e.g., concluding superiority or equivalence) will be based on pre-specified threshold values for posterior probability. The primary outcome of interest, the definitions for superiority, futility, etc. (i.e., the magnitude of treatment effect) and the threshold values of posterior probability required to reach conclusions for superiority, futility etc., will vary from intervention to intervention depending on the phase of investigation and the nature of the intervention being evaluated. All of these parameters will be pre-specified as part of the statistical design for each intervention trial.
In general, domains will be designed to evaluate treatment effect within four discrete clinical states: non-intubated patients, intubated patients with low respiratory system elastance (\<2.5 cm H2O/(mL/kg)), intubated patients with high respiratory system elastance (≥2.5 cm H2O/(mL/kg)), and patients requiring extracorporeal life support. Where appropriate, the model will specify dynamic borrowing between states to maximize statistical information available for trial conclusions. In this perpetual trial design, different interventions may be added or dropped over time.
Where possible, the platform will be embedded within existing data collection repositories to enable greater efficiency in outcome ascertainment. Standardized systems for acquiring both physiological and biological measurements are embedded in the platform, to be acquired at sites with appropriate training, expertise, and facilities to collect those measurements.
EXPAND-ECLS domain: The EXPAND-ECLS pilot trial is a multi-center, randomized, open-label, feasibility trial, embedded as a domain within the PRACTICAL platform trial. The ULTIMATE arm of this domain will evaluate the effect of ultra-low intensity ventilation facilitated by CO2 removal through VV-ECMO versus best current conventional ventilation on all-cause hospital mortality among patients with early moderate-severe AHRF with high respiratory system elastance receiving potentially injurious mechanical ventilation. The PROACTIVE arm of this domain will evaluate the effect of ECMO-facilitated strategy of earlier awakening, extubation, and rehabilitation versus best current conventional ventilation on all-cause hospital mortality among patients with early moderate-severe AHRF with high respiratory system elastance receiving potentially injurious mechanical ventilation.
Invasive Mechanical Ventilation (IMV) Strategies domain: The IMV Strategies domain will evaluate multiple novel invasive ventilation strategies in comparison to conventional lung-protective ventilation in patients with acute hypoxemic respiratory failure (AHRF). Multiple approaches to mechanical ventilation are used, and the optimal approach is unknown. An efficient strategy to identify the best strategy is to compare multiple potential approaches simultaneously to determine more rapidly (a) which interventions are least effective (and should be dropped), and (b) which interventions result in the best outcomes for patients. In the current domain design, we will compare the current recommended ventilation strategy to two new approaches: a strategy that targets lung-inflating (driving) pressure instead of lung-inflating (tidal) volume, and a strategy that aims to maintain an optimal level of breathing effort to prevent diaphragm atrophy and injury while maintaining safe lung-inflating pressures.
CORT-E2 domain: The Corticosteroid Early and Extended (CORT-E2) Trial is a phase III, multicentre Bayesian randomized controlled trial (RCT), which includes two cohorts within the domain; one examining the role of early corticosteroids as compared to not extending in persisting AHRF due to COVID or non-COVID (Extended Cohort).
ESCAPE domain: Evaluating Subphenotypes in Immunocompromized Patients with ARF (ESCAPE) Domain is a prospective, multicentre observational cohort study, to identify subphenotypes across immunocompromised patients with acute hypoxemic respiratory failure (AHRF) using clinical characteristics and biomarkers. This study will prospectively collect biomarkers at the onset of AHRF which will allow us to characterize the underlying pathophysiology of AHRF with better precision.
WAVEFORM domain: The Clinical Implications of Potentially Injurious Patient-Ventilator Interactions (WAVEFORM domain) a prospective, multicentre observational cohort study, that aims at understanding the short- and long-term clinical consequences of longitudinal exposure to abnormal patient ventilation interactions in patients with AHRF, role of sedation as a mediator in this relationship. It aims at also exploring the heterogeneity of treatment effect of various mechanical ventilation strategies tested in the IMV based on the presence and burden of abnormal patient-ventilator interactions.
FLUDRO domain: The Fludrocortisone in Acute Hypoxemic Respiratory Failure with Airspace Disease (FLUDRO-1) domain is a phase II I trial. The trial aims to provide direct clinical evidence to resolve a critical long-standing question regarding the use of steroids in the treatment of AHRF with airspace disease.
FAST-3 domain: The Nebulized Furosemide for the Treatment of Pulmonary Inflammation in Patients with Respiratory Failure Secondary to Pulmonary Infection domain is a phase III trial. It aims to use nebulized furosemide as supportive therapy to improve Advanced Respiratory Support (ARS) free days up to day 28 in critically ill patients with AHRF.
IMV-ECLS domain: The Invasive Mechanical Ventilation Strategies in Venovenous-Extracorporeal Life Support (PRESSURE; Positive Pressure to Maintain Lung Recruitment during Extracorporeal Life Support for Acute Hypoxemic Respiratory failure) is a pilot and feasibility trial. It aims to identify which positive end-expiratory pressure (PEEP) strategies improve lung function in patients with AHRF supported by ECLS.
IMPROV domain: The Inspiratory Muscle Training in Patients Receiving Ongoing Mechanical Ventilation is a pilot and feasibility RCT. It is designed to establish the feasibility of a definitive RCT of inspiratory muscle training to accelerate recovery from AHRF.
PRACTICAL Platform Inclusion Criteria:
Acute hypoxemic respiratory failure meeting all of the following criteria;
PRACTICAL Platform Exclusion Criteria:
EXPAND-ECLS Domain Inclusion Criteria:
EXPAND-ECLS Domain Exclusion Criteria:
IMV Domain Inclusion Criteria:
IMV Domain Exclusion Criteria:
CORT-E2 Domain Early Cohort Inclusion Criteria
CORT-E2 Domain Early Domain Exclusion Criteria
CORT-E2 Domain Extended Cohort Inclusion Criteria
CORT-E2 Domain Extended Cohort Exclusion Criteria
FLUDRO Domain Inclusion Criteria 1. Within 72 hours of admission to an ICU
FLUDRO Domain Exclusion Criteria
FAST-3 Domain Inclusion Criteria (must meet all 3 of the following)
Patient is in a PRACTICAL eligible platform state and requires advanced respiratory support (ARS) defined as one of the following:
a. Invasive mechanical ventilation with FiO2 > 40% b. Non-Invasive Ventilation (> 4 hours consecutively with FiO2 > 40%) defined as: i. CPAP or BiPAP (any settings or interface) ii. HFNC (flow > 40 liter per minute)
FAST-3 Domain Exclusion Criteria
ESCAPE Domain Inclusion Criteria
Patients may be enrolled from the wards or ICU.
Immunocompromised patients include:
Any patients who have undergone or autologous hematopoietic cell transplant in the prior 6 months (HCT).
ESCAPE Domain Exclusion Criteria
WAVEFORM Domain Inclusion Criteria
1. Patient is intubated at the time of eligibility assessment.
WAVEFORM Domain Exclusion Criteria
IMV-ECLS Domain Inclusion Criteria
1. Patients with AHRF (as defined in platform inclusion criteria #1 above) who have been consented for cannulation for VV-ECLS or who have been initiated on VV-ECLS within 6 hours at the time of randomization
IMV-ECLS Domain Exclusion Criteria 1. Patients receiving ECLS for the primary intention of extracorporeal CO2 removal 2. Patients expected to be liberated from ECLS within \<24 hours 3. History of recent pneumothorax or pneumomediastinum (\<3 months at the time of eligibility assessment/randomization) 4. Patients receiving ECLS for the primary intention of bridge to lung transplantation (at the time of eligibility assessment/randomization)
IMPROV Domain Inclusion Criteria
IMPROV Domain Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized to the this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
Other: Ultra-Protective Ventilation Facilitated by Extracorporeal Support · Other: Lung-Protective Ventilation (LPV) · Other: VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation
Patients on invasive mechanical ventilation in the low elastance, high elastance, and ECLS states will be randomized to minimum of one of two mechanical ventilation interventions (including conventional lung-protective ventilation as a control group). Most sites will randomize patients to two arms (one of which is the control group, LPV). A subset of sites will randomize patients to all three or four arms.
Other: Lung-Protective Ventilation (LPV) · Other: Driving Pressure-Limited Ventilation (DPL) · Other: Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS) · Other: Electrical impedance tomography (EIT)
Patients with acute hypoxemic respiratory failure (AHRF) requiring invasive or non-invasive respiratory support will be randomized in the Early Cohort to receive corticosteroid or usual care without corticosteroids. Patients treated with corticosteroids who still require invasive or non-invasive respiratory support after 10 days will be randomized in the Extended Cohort to extending corticosteroid use or stopping corticosteroids after 10 days.
Drug: Early Cohort corticosteroid dose · Drug: Extended Cohort corticosteroid dose · Drug: Usual care without routine corticosteroids · Drug: Usual care without extending corticosteroids
Patients with Respiratory Failure Secondary to Pulmonary Infection.
Drug: Drug 4 mL: · Drug: Drug 40 mg:
Patients with acute hypoxemic respiratory failure receiving extracorporeal life support will be randomized to one of three positive end-expiratory pressure (PEEP) strategies.
Other: PEEP-20 · Other: PEEP-AOP · Other: PEEP-10
Patients with acute hypoxemic respiratory failure with airspace disease will be randomized to usual care with or without fludrocortisone.
Drug: Usual care with fludrocortisone · Drug: Usual care without fludrocortisone
Patients with acute hypoxemic respiratory failure in the high elastance state will be randomized to ultra-protective ventilation facilitated by extracorporeal carbon dioxide removal or to VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation or to conventional lung-protective ventilation.
Other: Ultra-Protective Ventilation Facilitated by Extracorporeal Support · Other: Lung-Protective Ventilation (LPV) · Other: VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation
We will conduct a prospective, multicenter, observational study (no treatment arm is involved) in 7 ICUs in Canada over 3 years. We will include adult patients (≥18 years) admitted to the ICU with AHRF who have an underlying immunocompromised condition. Biomarker Collection: Samples for serum biomarkers will be collected within 24 hours of fulfilling inclusion criteria, on days 0, 3 and 7. We will collect biomarkers associated with inflammatory conditions, epithelial injury, endothelial dysfunction and coagulation abnormalities - which have been shown to characterize lung injury or critical illness. Data Collection: We will collect demographic, comorbidity, immunocompromised defining condition, clinical, respiratory physiology, and serum biomarker data for each patient.
Other: no treatment / intervention arm is involved
This domain studies inspiratory muscle training (IMT) during and after mechanical ventilation in patients with acute hypoxemic respiratory failure (AHRF).
Other: Usual care · Other: Early Routine IMT
This domain primarily aims at understanding the short-and long-term clinical consequences of longitudinal exposure to abnormal patient ventilator interactions.
Other: no treatment / intervention arm is involved.
Patients randomized to this intervention group will receive VV-ECMO with the ventilator set to minimize driving pressure and respiratory rate for ultra-protective ventilation.
Patients randomized to LPV will receive standard of care lung-protective ventilation with conventional limits on tidal volume and plateau airway pressure.
Patients randomized to DPL will receive mechanical ventilation set to maintain a safe limit on driving pressure and plateau airway pressure, without less for the tidal volume.
Patients randomized to LDPVS will have ventilation and sedation adjusted to maintain lung-distending pressure and respiratory effort in a safe target range.
Patients randomized to receive corticosteroids will receive dexamethasone 20mg daily for 5 days and then 10mg for an additional 5 days, for a total of 10 days from the time of randomization (or until ICU discharge or death, whichever comes first); after 10 days dexamethasone will be stopped without a taper.
Patients randomized to receive extended corticosteroids will receive dexamethasone 10mg for an additional 10 days. At the end of the additional 10 days (day 20 of corticosteroids), the dexamethasone dose will be halved to 5mg for another 5 days (to reduce the risk of adrenal insufficiency) and then stopped (a total of 25 days or until ICU discharge or death, whichever comes first).
Patients randomized to this arm will be managed according to usual care. They will receive corticosteroids only if prescribed by the clinician.
Corticosteroids will stop after 10 days. Other management will be according to usual care. Patients will receive corticosteroids only if prescribed by the clinician.
Best practice standard of care prescribed by treating team + fludrocortisone 50μg enterally daily for 7 days.
Best practice standard of care prescribed by treating team without fludrocortisone. After randomization, if a clinical indication develops for fludrocortisone as part of standard of care, administration of fludrocortisone is not prohibited. Any fludrocortisone administered to participants in the control arm will be documented.
4 mL of nebulized 0.9% saline minutes every 6 hours over 30 minutes every 6 hours.
40 mg of nebulized furosemide in 4 mL of saline nebulized over 30 minutes every 6 hours
fixed high positive end-expiratory pressure at 20 cmH2O
positive end-expiratory pressure set according to airway opening pressure
fixed lower positive end-expiratory pressure at 10 cmH2O
Patients randomized to this intervention group will receive VV-ECMO where the sedation will be reduced and the ventilator will will be adjusted to facilitate spontaneous breathing.
Patients randomized to EIT will have PEEP titration compared via the Overdistension Collapse Intercept (ODCL) versus that obtained using a standard high PEEP table.
This trial is a prospective, multicenter, observational study (no treatment arm is involved).
Patients will be treated according to usual care.
* Training commences once patients meet readiness to wean criteria * 3 sets of 10 breaths, delivered twice daily using a device placed at the airway opening to apply an external resistive pressure load, until hospital discharge, death, or day 45 after randomization, whichever occurs first. * Device load will initially be set to 30% of the MIP. * Device load will be titrated upward (in increments of 5-10% of MIP, to a maximum of 60% of MIP) as needed to achieve a modified Borg dyspnea score of 7/10 or visible accessory muscle use.
This trial is a prospective, multicenter, observational study (no treatment arm is involved).
EXPAND-ECLS domain - determine the feasibility of recruiting 100 patients over 2 years of active enrolment, as well as assess the rate of participant recruitment and understand the barriers to enrollment.
Record total number of patients randomized, total number of patients eligible yet not randomized, and the number of active randomizing sites on a monthly basis. This will include evaluating the validity and appropriateness of inclusion and exclusion criteria, trial acceptability, and reasons for lack of consent or withdrawal.
Time frame: 2 years of active site enrollment.
FLUDRO-1 and IMV domains - ventilator-free days to day 28 in DPL vs LPV (DRIVE RCT)
Ventilator-free days to day 28 is computed as an ordinal scale ranging between -1 to 28. Patients who die in hospital will be assigned a value of -1. Otherwise the endpoint will be computed from the number of days alive and free of ventilation in the period between the day the patient is liberated from mechanical ventilation and day 28.
Time frame: Day 28 post randomization
IMV domain - adherence to LDPVS management (LANDMARK RCT)
Adherence to LDPVS management will be measured in terms of the proportion of protocol-specified measurements of respiratory effort that are on target during the intervention period.
Time frame: Day 28
IMV domain - probability of achieving and maintaining lung- and diaphragm-protective targets during mechanical ventilation (LANDMARK RCT)
Lung- and diaphragm-protective targets are defined as an estimated dynamic trans pulmonary driving pressure ≤23 cm H2O and a Pocc value between -6 to -20 cm H2O.
Time frame: Day 28
IMV domain - protocol adherence (EIT intervention)
Protocol adherence will be measured as a binary outcome daily, while patients are receiving EIT. The target protocol adherence across patients is ≥80%.
Time frame: Day 9
CORT-E2 domain - 60-day mortality from the day of randomization
Time frame: Day 60
FLUDRO-1 domain - Successful enrollment of participants
Protocol adherence: e.g., proportion of participants randomized to fludrocortisone who received the study drug as specified in the protocol; Consent rate; Early withdrawal from domain intervention; Outcome completeness
Time frame: 18-month enrolment period across three platform trials (PRACTICAL, REMAP-CAP and ATTACC-CAP)
FAST-3 domain - Advanced respiratory support free days
Advanced respiratory support free days (ARSFDs) to day 28, a composite outcome including mortality and requirement for respiratory support
Time frame: Day 28
IMV-ECLS domain - feasibility of enrollment and protocol adherence
Feasibility of enrollment defined as ≥1 patient enrolled per month per site. Protocol adherence defined as ≥90% of patients initiated on assigned PEEP strategy within 6 hours of ECLS cannulation and ≥90% average protocol adherence across participants.
Time frame: For feasibility of enrollment: 2 years of active site enrollment; For protocol adherence, these will be evaluated at 7 days (once the intervention period ends)
ESCAPE domain - 28-day all-cause mortality
Time frame: 28-day
IMPROV domain - recruitment rate, protocol adherence, and vital status
≥0.75 patients randomized per site per month, Protocol adherence defined as \> 80% across participants, and ≥89% ascertainment of vital status and days alive and at home at day 90.
Time frame: Throughout trial enrollment for recruitment rate and protocol adherence, and up to day 90 for vital status.
WAVEFORM domain
Duration of mechanical ventilation (MV)
Time frame: considering death as a competing event
To assess adherence to our explicit mechanical ventilation protocols.
Adherence to protocol defined as \>80% of patients having \<20% of monitored values determined to be major protocol deviations.
Time frame: 48 hours
To measure and understand the reasons for crossovers in each group
Success for lack of crossovers defined as \<10% of crossovers between groups (when not allowed by protocol) in either direction.
Time frame: 2 years
Duration of mechanical ventilation during index ICU admission
Measured in CORT-E2, IMV, IMV-ECLS and EXPAND-ECLS domains
Time frame: Until ICU discharge, typically within 28 days
Mortality at other endpoints
Measured in CORT-E2, ESCAPE, FAST-3, IMV, IMV-ECLS, IMPROV and EXPAND-ECLS and WAVEFORM domains
Time frame: ICU discharge, hospital discharge, day 30, 180 for CORT E2, IMV, IMV ECLS, and EXPAND ECLS.For ESCAPE:hospital mortality @ 60 days and 6 months.For FAST 3:all cause mortality @ 60 days post enrollment.For IMPROV:day 90.For WAVEFORM:day 28 after inclusion
Vital status
Measured in IMPROV domain
Time frame: Day 90 and at 6 months
Duration of ICU admission
Measured in FAST-3, IMV, IMV-ECLS and EXPAND-ECLS and WAVEFORM domains
Time frame: Until ICU discharge, typically within 28 days
Hospital length of stay
Measured in CORT-E2, FAST-3, IMV, IMV-ECLS and WAVEFORM domains
Time frame: Until hospital discharge, assessed up to 4 weeks
ICU and hospital free days
Measured in FAST-3, IMPROV domains
Time frame: For FAST-3: ICU discharge, hospital discharge, Day 28. For IMPROV: Day 90.
Discharge disposition.
Measured in IMV, IMV-ECLS, IMPROV domains. Location to which patient is discharged (e.g., home, weaning facility, etc.)
Time frame: Until hospital discharge, assessed up to 4 weeks
Days alive and at home to day 90
Measured in IMV, IMV-ECLS and FLUDRO-1 and WAVEFORM domains
Time frame: Day 90
Need for ICU readmission prior to hospital discharge
Measured in IMV, IMV-ECLS domains
Time frame: Until hospital discharge, assessed up to 4 weeks
Duration of NIV
Measured in CORT-E2 domain
Time frame: Until ICU discharge, typically within 28 days
Duration of supplemental oxygen use
Measured in CORT-E2 domain
Time frame: Until ICU discharge, typically within 28 days
Need for ECLS
Measured in CORT-E2 domain
Time frame: Until ICU discharge, typically within 28 days
Duration of ECLS, only for patients who require ECLS
Measured in CORT-E2, IMV-ECLS domains.
Time frame: Until ICU discharge, typically within 28 days
Ventilator-free days until day 30 for CORT-E2; until day 28 for FAST-3, FLUDRO-1, ULTIMATE and WAVEFORM( ordinal scale composed of survival to hospital discharge, days alive and free of ventilation where death in the hospital is assigned a score of -1).
Measured in CORT-E2, FAST-3, FLUDRO-1, ULTIMATE and WAVEFORM domains.
Time frame: Until day 30 for CORT-E2, and until day 28 for FAST-3, FLUDRO-1, ULTIMATE and WAVEFORM
EQ-5-D at day 180
Measured in CORT-E2, FAST-3, IMV, IMV-ECLS, IMPROV, WAVEFORM domains
Time frame: For CORT-E2, FAST-3, IMV, and IMV-ECLS domains: Day 180; For IMPROV domain: Day 90 and Day 180.
Montreal Cognitive Assessment (MoCA) At day 180
Measured in FAST-3 domain
Time frame: Day 180
Complications from corticosteroids.
Measured in CORT-E2 domain. Hypernatremia, hyperglycemia, delirium, clinically important GI bleeding, nosocomial infection, neuromuscular weakness. Measured in FLUDRO-1 domain: Hypernatremia, Hyperglycemia, Hypokalemia, Clinically important gastrointestinal bleeding, New nosocomial infection
Time frame: Until hospital discharge, assessed up to 4 weeks
Reintubation during index ICU admission
Measured in IMV, IMV-ECLS domains
Time frame: Until ICU discharge, typically within 28 days
Number of reintubations up to tracheostomy during index hospitalization
Measured in IMPROV domain
Time frame: Until hospital discharge
Tracheostomy during index ICU admission
Measured in IMV, IMV-ECLS, IMPROV domains
Time frame: Until ICU discharge, typically within 28 days
Re-cannulation to ECLS during index ICU admission
Measured in IMV-ECLS domain
Time frame: Until ICU discharge, typically within 28 days
Sequential Organ Failure Assessment (SOFA) score
Measured in IMV, IMV-ECLS domains
Time frame: Daily, for duration of intervention
Respiratory mechanics and gas exchange - Driving pressure.
Measured in IMV, IMV-ECLS domains.
Time frame: Daily, for duration of intervention
Respiratory mechanics and gas exchange - Pocc.
Measured in IMV, IMV-ECLS domains.
Time frame: Daily, for duration of intervention
Respiratory mechanics and gas exchange - P0.1
Measured in IMV, IMV-ECLS domains.
Time frame: Daily, for duration of intervention
Respiratory mechanics and gas exchange - plateau airway pressure
Measured in IMV, IMV-ECLS domains.
Time frame: Daily, for duration of intervention
Respiratory mechanics and gas exchange - P/F ratio
Measured in IMV, IMV-ECLS domains.
Time frame: Daily, for duration of intervention
Respiratory mechanics and gas exchange - ventilatory ratio
Measured in IMV domain.
Time frame: Daily, for duration of intervention
Diaphragm thickness
Measured in IMV domain
Time frame: Daily, for duration of intervention
Maximal diaphragm thickening fraction
Measured in IMV domain
Time frame: During first SBT
Survival status at disconnection from mechanical ventilation (dead or alive)
Measured in EXPAND-ECLS domain
Time frame: Until day 28
Organ failure-free days
Measured in ESCAPE, FLUDRO-1 domains
Time frame: Until day 28
Serious adverse events (SAEs)
Serious adverse events (SAEs) related to the intervention measured in FAST-3 domain
Time frame: Throughout the trial
Modified Lung Injury Score (mLIS)
Measured in IMV-EIT intervention. Calculated daily up until study day 10 in patients who are alive and continue to have acute hypoxemic respiratory failure requiring invasive mechanical ventilation.
Time frame: Until day 10
Number of days from first SBT to disconnection from mechanical ventilation
Measured in IMPROV domain - final date of extubation or the first day of continuous tracheostomy mask for at least 24 hours, provided ventilator support is not resumed during the index ICU admission.
Time frame: Until ICU discharge
Barotrauma during hospital admission
Measured in IMPROV domain including pneumothorax, pneumomediastinum, subcutaneous emphysema
Time frame: Until 45 days or hospital discharge
Cardiac arrest during hospital admission
Measured in IMPROV domain
Time frame: Until 45 days or hospital discharge
30 second sit to stand test at ICU discharge and hospital discharge
Measured in IMPROV domain
Time frame: Until ICU discharge, typically within 28 days
Modified Medical Research Council (mMRC) Dyspnea Scale
Measured in IMPROV domain
Time frame: At ICU discharge, Day 90, Day 180
Physical function (Activity Measure for Post-Acute Care)
Measured in IMPROV domain
Time frame: At ICU discharge, Day 90, Day 180
Days alive at day 180 after inclusion
Measured in WAVEFORM domains
Time frame: Day 180
Incidence of abnormal PVIs in each ventilation strategy
Measured in WAVEFORM domain
Time frame: 7 days
Sedation and NMBA use, type, simultaneous and cumulative dose
Measured in WAVEFORM domain
Time frame: 7 days, 28 days
Vasopressor use, type, simultaneous and cumulative dose
Measured in WAVEFORM domain
Time frame: 7 days, 28 days
PTSD symptoms (IES-R)
Measured in WAVEFORM domain
Time frame: Day 180
Cognitive status (MoCA-BLIND)
Measured in WAVEFORM domain
Time frame: Day 180
Showing the first 100 of 103 sites across 10 countries. Choose a country and city above to see the rest.
Started Apr 2023 (actual). Primary completion is estimated for Mar 2027, 47 months after the start.
Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 47 months is above that.
Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto →